Table 3.

Overall model of impact on the mortality rate of different campaigns with oral polio vaccine (OPV).

Variable	Campaign OPV(1) MRR	p-value	Campaign OPV(2) MRR	p-value	Campaign OPV(3) MRR	p-value
Campaign-OPV	0.81 (0.68–0.95)	0.011	0.87 (0.79–0.96)	0.007	0.77 (0.56–1.08)m	0.13
					0.80 (0.57–1.12)b	0.20
					0.85 (0.71–1.02)t	0.09
Campaign-OPV + VASa	1.10 (0.82–1.48)	0.53	1.06 (0.79–1.41)	0.70	1.08 (0.81–1.44)	0.61
Campaign-VASa	1.04 (0.80–1.35)	0.76	1.05 (0.81–1.36)	0.72	1.03 (0.80–1.34)	0.81
Campaign-H1N1a	1.86 (1.02–3.42)	0.04	2.10 (1.13–3.92)	0.02	1.90 (0.98–3.70)	0.06
Campaign-MVa	1.24 (0.74–2.09)	0.42	1.26 (0.74–2.12)	0.39	1.21 (0.72–2.04)	0.48
Calendar year, 0–5 monthsb	0.95 (0.93–0.98)	0.001	0.95 (0.93–0.98)	<0.001	0.96 (0.93–0.98)	0.001
Calendar year, 6–11 monthsb	0.89 (0.85–0.94)	<0.001	0.89 (0.85–0.94)	<0.001	0.90 (0.85–0.95)	<0.001
Calendar year, >12 monthsb	0.83 (0.73–0.94)	0.004	0.83 (0.73–0.94)	0.004	0.84 (0.73–0.96)	0.01

^aafter-campaign vs before campaign.

^bCalendar year trend in the age-groups of 0–5, 6–11, and >12 months of age.

⁽¹⁾After-campaign vs before campaign.

⁽²⁾Continuous dose-response for OPV.

⁽³⁾After-campaign vs before campaign; OPV-type: monovalent^m, bivalent^b, trivalent^t.^.